The main risk is sequencing, not survival. IonQ has cash, strategic relevance, and better control points after
SkyWater, but the equity still needs timely proof that
Superion can be manufactured, delivered, accepted, and embedded into funded customer workflows before the market stops rewarding roadmap optionality.